Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa.

PubWeight™: 2.17‹?› | Rank: Top 2%

🔗 View Article (PMC 171800)

Published in Antimicrob Agents Chemother on June 01, 1990

Authors

H Yoshida1, M Nakamura, M Bogaki, S Nakamura

Author Affiliations

1: Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.

Articles citing this

Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42

Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22

Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother (1994) 2.47

Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43

Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2000) 2.07

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84

nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.73

Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother (1995) 1.72

Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.69

Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Antimicrob Agents Chemother (1995) 1.61

Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 1.60

Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.55

Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob Agents Chemother (1991) 1.42

Mechanisms of resistance to quinolones. Drugs (1993) 1.41

Broad-host-range gyrase A gene probe. Antimicrob Agents Chemother (1990) 1.38

A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.37

Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother (1992) 1.37

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother (1991) 1.24

Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet (2012) 1.20

Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob Agents Chemother (1995) 1.17

Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother (1995) 1.13

Mechanisms of quinolone resistance. Infection (1994) 1.13

Type II topoisomerase quinolone resistance-determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance. Antimicrob Agents Chemother (2002) 1.11

Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 1.09

The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother (2014) 1.08

Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob Agents Chemother (2002) 1.04

Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother (1999) 1.03

Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Antimicrob Agents Chemother (1996) 1.01

Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob Agents Chemother (1999) 0.99

Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother (1993) 0.95

Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA. Antimicrob Agents Chemother (1991) 0.91

Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother (1999) 0.91

Tracking down antibiotic-resistant Pseudomonas aeruginosa isolates in a wastewater network. PLoS One (2012) 0.89

Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother (2012) 0.87

A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry. Mol Cell Proteomics (2014) 0.81

Molecular epidemiology of mutations in antimicrobial resistance loci of Pseudomonas aeruginosa isolates from cystic fibrosis airways. Antimicrob Agents Chemother (2016) 0.75

Articles cited by this

Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A (1977) 18.37

Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol (1969) 8.78

Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20

Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00

Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95

Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67

Studies on the mechanism of action of nalidixic acid. Antimicrob Agents Chemother (1973) 5.64

Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc Natl Acad Sci U S A (1978) 5.33

Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96

Mechanisms of action of and resistance to ciprofloxacin. Am J Med (1987) 4.46

Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69

gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother (1989) 3.67

Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1988) 3.13

Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04

Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother (1989) 2.05

Low- and intermediate-copy-number cloning vectors based on the Pseudomonas plasmid pVS1. Antonie Van Leeuwenhoek (1988) 0.96

Articles by these authors

Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79

Antisense transcription in the mammalian transcriptome. Science (2005) 15.69

Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71

Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother (1975) 8.67

Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother (1976) 7.92

Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61

CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07

Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (1979) 6.56

Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother (1975) 6.38

Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30

Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19

Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95

In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother (1983) 5.45

Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50

Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science (1993) 4.39

Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun (1993) 4.32

Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96

Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation (1995) 3.82

gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother (1989) 3.67

New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. J Bacteriol (1981) 3.65

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord (2006) 3.55

Discovery of a cool planet of 5.5 Earth masses through gravitational microlensing. Nature (2006) 3.53

On the process of cellular division in Escherichia coli: nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet (1983) 3.43

Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett (1996) 3.40

Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Plant Cell Physiol (1996) 3.30

Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol (2001) 3.26

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med (2001) 3.23

Effective elimination of drug resistance and sex factors in Escherichia coli by sodium dodecyl sulfate. J Bacteriol (1968) 3.22

Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20

Electric-field-induced superconductivity in an insulator. Nat Mater (2008) 3.17

Light-dependent translocation of a phytochrome B-GFP fusion protein to the nucleus in transgenic Arabidopsis. J Cell Biol (1999) 3.14

Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids. Antimicrob Agents Chemother (1978) 3.12

Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol (1993) 3.08

Noggin is a mesenchymally derived stimulator of hair-follicle induction. Nat Cell Biol (1999) 2.99

Diet-dependent shifts in the bacterial population of the rumen revealed with real-time PCR. Appl Environ Microbiol (2001) 2.98

Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs in the control of rel/NF-kappaB-dependent innate immune responses. Genes Dev (2001) 2.96

AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93

Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem (1991) 2.89

The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci U S A (1999) 2.87

Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84

Molecular cloning and sequence determination of cDNAs for alpha subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain. Proc Natl Acad Sci U S A (1986) 2.83

Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science (1994) 2.78

Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science (1987) 2.75

Primary structure of elongation factor Tu from Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.72

Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran. Science (1999) 2.59

Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother (1983) 2.58

C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci U S A (1994) 2.57

Isolation of a second yeast Saccharomyces cerevisiae gene (GPA2) coding for guanine nucleotide-binding regulatory protein: studies on its structure and possible functions. Proc Natl Acad Sci U S A (1988) 2.54

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol (1996) 2.50

Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48

Nucleotide sequence of the asnA gene coding for asparagine synthetase of E. coli K-12. Nucleic Acids Res (1981) 2.42

Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun (1995) 2.42

Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol (2000) 2.36

Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29

Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord (2006) 2.28

Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature (1991) 2.28

Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci U S A (1990) 2.26

Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv (1999) 2.23

Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay. Virology (1999) 2.21

Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck (1997) 2.21

Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol (2009) 2.20

Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem (1999) 2.19

Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17

Genetic mutations in exons 3 and 4 of the pancreatic secretory trypsin inhibitor in patients with pancreatitis. J Gastroenterol (2001) 2.17

Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. Am J Physiol Lung Cell Mol Physiol (2001) 2.16

Occurrence in Saccharomyces cerevisiae of a gene homologous to the cDNA coding for the alpha subunit of mammalian G proteins. Proc Natl Acad Sci U S A (1987) 2.15

Functional assignment of the ORF2-iscS-iscU-iscA-hscB-hscA-fdx-ORF3 gene cluster involved in the assembly of Fe-S clusters in Escherichia coli. J Biochem (1999) 2.15

Surgical anatomy of the hepatic veins and the inferior vena cava. Surg Gynecol Obstet (1981) 2.12

Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet (1997) 2.12

Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10

Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10

Discovery of a Jupiter/Saturn analog with gravitational microlensing. Science (2008) 2.09

Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res (1999) 2.07

Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol (1999) 2.07

Unique features of the CAG repeats in Machado-Joseph disease. Nat Genet (1995) 2.06

Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res (2002) 2.06

Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor. Nucleic Acids Res (1985) 2.06

Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med (1999) 2.05

Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat. J Virol (1989) 2.03

Anomalous origin of the left coronary artery from the pulmonary artery. New operative technique. J Thorac Cardiovasc Surg (1993) 2.02

Two cases of bilateral bronchial artery varices: one with and one without bilateral coronary-to-pulmonary artery fistulas. Review and characterization of the clinical features of bronchial artery varices reported in Japan. Clin Radiol (2012) 2.00

Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science (1992) 1.98

Detection of Norwalk-like virus genes in the caecum contents of pigs. Arch Virol (1998) 1.97

Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (1996) 1.97

Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins. Haemostasis (1978) 1.96

Complete nucleotide sequence of the gene for human interleukin 1 alpha. Nucleic Acids Res (1986) 1.95

Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J (2001) 1.95

Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest (1998) 1.95

Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem (1994) 1.94